GB Orphan Designation Number: PLGB 00101/1191/OD1 ADCETRIS It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate. GB Orphan Designation Number: PLGB 50412/0023/OD1 ADAKVEOĪdakveo is indicated for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. ABECMAĪbecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
Where you are instructed to see a numbered section for more information, you can do so in the Summary of Product Characteristics (SmPC) for each product. The list may be searched by pressing “CTRL+F” and entering a key word or phrase. Orphan registered products are listed in alphabetical order by trade name.
0 kommentar(er)
